LRRK2 and Parkinson disease: They found that a-GAL A activity was lower in PD cases compared to controls, even excluding all GBA and LRRK2 G2019S carriers and early onset PD cases (2.85 μmol/L/h versus 3.12 μmol/L/h, p = 0.018); this difference was significant after stratifying by sex too.